ArticleWorld journal of gastroenterology2003
Codon 249 mutation in exon 7 of p53 gene in plasma DNA: maybe a new early diagnostic marker of hepatocellular carcinoma in Qidong risk area, China.
Article in World journal of gastroenterology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 60 citations in OpenAlex.
- Pooled it
- Population attributable risk of aflatoxin-related liver cancer: systematic review and meta-analysis.European journal of cancer (Oxford, England : 1990) · 2012Pooled it
- Review
- Fifty Years of Aflatoxin Research in Qidong, China: A Celebration of Team Science to Improve Public Health.Toxins · 2025Review
- Article
- Somatic Mutations in Circulating Cell-Free DNA and Risk for Hepatocellular Carcinoma in Hispanics.International journal of molecular sciences · 2021Article
- Pathogens and Carcinogenesis: A Review.Biology · 2021Review
- Identification of Potential Biomarkers for Liver Cancer Through Gene Mutation and Clinical Characteristics.Frontiers in oncology · 2021Article
- The value of liquid biopsy in the diagnosis and staging of hepatocellular carcinoma: a systematic review.Translational gastroenterology and hepatology · 2021Article
- Liquid biopsy in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA.Molecular cancer · 2019Review
- It takes a team: a gain-of-function story of p53-R249S.Journal of molecular cell biology · 2019Review
- Qidong: a crucible for studies on liver cancer etiology and prevention.Cancer biology & medicine · 2019Article
- Liquid biopsies for hepatocellular carcinoma.Translational research : the journal of laboratory and clinical medicine · 2018Review
- Prevalence of Aflatoxin-AssociatedCancer prevention research (Philadelphia, Pa.) · 2018Article
- A Review of Circulating Tumor DNA in Hepatobiliary Malignancies.Frontiers in oncology · 2018Review
- Liquid Biopsy and its Potential for Management of Hepatocellular Carcinoma.Journal of gastrointestinal cancer · 2016Review
- DNA markers in molecular diagnostics for hepatocellular carcinoma.Expert review of molecular diagnostics · 2014Review
- Novel p53 codon 240 Ser > Thr coding region mutation in the patients of oral squamous cell carcinoma (OSCC).Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- Liquid biopsy: monitoring cancer-genetics in the blood.Nature reviews. Clinical oncology · 2013Review
- Hepatocellular carcinoma and liver cirrhosis TP53 mutation analysis reflects a moderate dietary exposure to aflatoxins in Espírito Santo State, Brazil.Molecular biology reports · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimOne of the characteristics of hepatocellular carcinoma (HCC) in Qidong area is the selective mutation resulting in a serine substitution at codon 249 of the p53 gene (1, 20), and it has been identified as a "hotspot" mutation in heptocellular carcinomas occurring in populations exposed to aflatoxin and with high prevalence of hepatitis B virus carriers (2,3,9, 10,16,24). We evaluated in this paper whether this "hotspot" mutation could be detected in cell-free DNA circulating in plasma of patients with hepatocellular carcinoma and cirrhosis in Qidong, China, and tried to illustrate the significance of the detection of this molecular biomarker.
methodsWe collected blood samples from 25 hepatocellular carcinoma patients, 20 cirrhotic patients and 30 healthy controls in Qidong area. DNA was extracted and purified from 200 microl of plasma from each sample. The 249(Ser) p53 mutation was detected by restriction digestion analysis and direct sequencing of exon-7 PCR products.
resultsWe found in exon 7 of p53 gene G-T transversion at the third base of codon 249 resulting 249(Arg) - 249(Ser) mutation in 10/25 (40 %) hepatocellular carcinoma cases, 4/20 (20 %) cirrhotics, and 2/30 (7 %) healthy controls. The adjusted odds ratio for having the mutation was 22.1(95 % CI, 3.2-91.7) for HCC cases compared to controls.
conclusionThese data show that the 249(Ser) p53 mutation in plasma is strongly associated with hepatocellular carcinoma in Qidong patients. We found this mutation was also detected, although it was at a much lower frequency, in plasma DNA of Qidong cirrhotics and healthy controls; We consider that these findings, together with the usual method of HCC diagnosis, will give more information in early diagnosis of HCC, and 249(Ser) p53 mutation should be developed to a new early diagnostic marker for HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.